Sphingolipids as Targets for Treatment of Fungal Infections

References

• Martin GS , ManninoDM, EatonS, MossM. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med.348 (16), 1546–1554 (2003).
   PubMed Web of Science ®Google Scholar
• Mcneil MM , NashSL, HajjehRAet al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin. Infect. Dis.33 (5), 641–647 (2001).
   PubMed Web of Science ®Google Scholar
• Brown GD , DenningDW, GowNA, LevitzSM, NeteaMG, WhiteTC. Hidden killers: human fungal infections. Sci. Transl. Med.4 (165), 165rv113 (2012).
   Web of Science ®Google Scholar
• Richardson MD . Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother.56 (Suppl. 1), i5–i11 (2005).
   PubMed Web of Science ®Google Scholar
• Bassetti M , RighiE. Overview of fungal infections – the Italian experience. Semin. Respir. Crit. Care Med.36 (5), 796–805 (2015).
   PubMedGoogle Scholar
• Vandeputte P , FerrariS, CosteAT. Antifungal resistance and new strategies to control fungal infections. Int. J. Microbiol.2012, 713687 (2012).
   PubMedGoogle Scholar
• Roemer T , KrysanDJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb. Perspect. Med.4 (5), pii: a019703 (2014).
   PubMed Web of Science ®Google Scholar
• Cowen LE . The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol.6 (3), 187–198 (2008).
   PubMed Web of Science ®Google Scholar
• Heung LJ , LubertoC, Del PoetaM. Role of sphingolipids in microbial pathogenesis. Infect. Immun.74 (1), 28–39 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng J , ParkTS, ChioLC, FischlAS, YeXS. Induction of apoptosis by sphingoid long-chain bases in Aspergillus nidulans. Mol. Cell. Biol.23 (1), 163–177 (2003).
   PubMed Web of Science ®Google Scholar
• Dickson RC , LesterRL. Sphingolipid functions in Saccharomyces cerevisiae. Biochim. Biophys. Acta1583 (1), 13–25 (2002).
   PubMed Web of Science ®Google Scholar
• Obeid LM , OkamotoY, MaoC. Yeast sphingolipids: metabolism and biology. Biochim. Biophys. Acta1585 (2), 163–171 (2002).
   PubMedGoogle Scholar
• Zhong W , JeffriesMW, GeorgopapadakouNH. Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species. Antimicrob. Agents Chemother.44 (3), 651–653 (2000).
   PubMed Web of Science ®Google Scholar
• Levery SB , MomanyM, LindseyRet al. Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc: ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth. FEBS Lett.525 (1), 59–64 (2002).
   PubMedGoogle Scholar
• Rittershaus PC , KechichianTB, AllegoodJCet al. Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. J. Clin. Invest.116 (6), 1651–1659 (2006).
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH . Antifungals targeted to sphingolipid synthesis: focus on inositol phosphorylceramide synthase. Expert Opin. Investig. Drugs9 (8), 1787–1796 (2000).
   PubMed Web of Science ®Google Scholar
• Tavares PM , ThevissenK, CammueBPet al. In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis. Antimicrob. Agents Chemother.52 (12), 4522–4525 (2008).
   PubMed Web of Science ®Google Scholar
• Thevissen K , De Mello TavaresP, XuDet al. The plant defensin RsAFP2 induces cell wall stress, septin mislocalization and accumulation of ceramides in Candida albicans. Mol. Microbiol.84 (1), 166–180 (2012).
   PubMed Web of Science ®Google Scholar
• Da Silva AFC , RodriguesML, FariasSE, AlmeidaIC, PintoMR, Barreto-BergterE. Glucosylceramides in Colletotrichum gloeosporioides are involved in the differentiation of conidia into mycelial cells. FEBS Lett.561 (1), 137–143 (2004).
   PubMedGoogle Scholar
• Nimrichter L , Barreto-BergterE, Mendonca-FilhoRRet al. A monoclonal antibody to glucosylceramide inhibits the growth of Fonsecaea pedrosoi and enhances the antifungal action of mouse macrophages. Microb. Infect.6 (7), 657–665 (2004).
   PubMed Web of Science ®Google Scholar
• Rodrigues ML , TravassosLR, MirandaKRet al. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect. Immun.68 (12), 7049–7060 (2000).
   PubMed Web of Science ®Google Scholar
• Rollin-Pinheiro R , Liporagi-LopesLC, De MeirellesJV, SouzaLM, Barreto-BergterE. Characterization of Scedosporium apiospermum glucosylceramides and their involvement in fungal development and macrophage functions. PLoS ONE9 (5), e98149 (2014).
   PubMed Web of Science ®Google Scholar
• Pinto MR , RodriguesML, TravassosLR, HaidoRM, WaitR, Barreto-BergterE. Characterization of glucosylceramides in Pseudallescheria boydii and their involvement in fungal differentiation. Glycobiology12 (4), 251–260 (2002).
   PubMed Web of Science ®Google Scholar
• Mor V , RellaA, FarnoudAMet al. Identification of a new class of antifungals targeting the synthesis of fungal sphingolipids. MBio6 (3), e00647 (2015).
   PubMed Web of Science ®Google Scholar
• Kathiravan MK , SalakeAB, ChotheASet al. The biology and chemistry of antifungal agents: a review. Bioorg. Med. Chem.20 (19), 5678–5698 (2012).
   PubMed Web of Science ®Google Scholar
• Bennett JE , DismukesWE, DumaRJet al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med.301 (3), 126–131 (1979).
   PubMed Web of Science ®Google Scholar
• Loyse A , DromerF, DayJ, LortholaryO, HarrisonTS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J. Antimicrob. Chemother.68 (11), 2435–2444 (2013).
   PubMed Web of Science ®Google Scholar
• Jin H , MccafferyJM, GroteE. Ergosterol promotes pheromone signaling and plasma membrane fusion in mating yeast. J. Cell Biol.180 (4), 813–826 (2008).
   PubMedGoogle Scholar
• Heese-Peck A , PichlerH, ZanolariB, WatanabeR, DaumG, RiezmanH. Multiple functions of sterols in yeast endocytosis. Mol. Biol. Cell13 (8), 2664–2680 (2002).
   PubMedGoogle Scholar
• Kato M , WicknerW. Ergosterol is required for the Sec18/ATP-dependent priming step of homotypic vacuole fusion. EMBO J.20 (15), 4035–4040 (2001).
   PubMedGoogle Scholar
• Bagnat M , KeranenS, ShevchenkoA, ShevchenkoA, SimonsK. Lipid rafts function in biosynthetic delivery of proteins to the cell surface in yeast. Proc. Natl Acad. Sci. USA97 (7), 3254–3259 (2000).
   PubMedGoogle Scholar
• Zavrel M , WhiteTC. Medically important fungi respond to azole drugs: an update. Future Microbiol.10 (8), 1355–1373 (2015).
   PubMed Web of Science ®Google Scholar
• Lemke A , KiderlenAF, KayserO. Amphotericin B. Appl. Microbiol. Biotechnol.68 (2), 151–162 (2005).
   PubMed Web of Science ®Google Scholar
• Gray KC , PalaciosDS, DaileyIet al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl Acad. Sci. USA109 (7), 2234–2239 (2012).
   PubMed Web of Science ®Google Scholar
• Mesa-Arango AC , ScorzoniL, ZaragozaO. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front. Microbiol.3, 286 (2012).
   PubMedGoogle Scholar
• Sangalli-Leite F , ScorzoniL, Mesa-ArangoACet al. Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect.13 (5), 457–467 (2011).
   PubMedGoogle Scholar
• Lupetti A , DanesiR, CampaM, Del TaccaM, KellyS. Molecular basis of resistance to azole antifungals. Trends Mol. Med.8 (2), 76–81 (2002).
   PubMed Web of Science ®Google Scholar
• Fromtling RA . Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev.1 (2), 187–217 (1988).
   PubMedGoogle Scholar
• Perfect JR , DurackDT, HamiltonJD, GallisHA. Failure of ketoconazole in cryptococcal meningitis. JAMA247 (24), 3349–3351 (1982).
   PubMedGoogle Scholar
• Boogaerts MA , MaertensJ, Van Der GeestRet al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob. Agents Chemother.45 (3), 981–985 (2001).
   PubMed Web of Science ®Google Scholar
• Denning DW , VenkateswarluK, OakleyKLet al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother.41 (6), 1364–1368 (1997).
   PubMed Web of Science ®Google Scholar
• Johnson LB , KauffmanCA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36 (5), 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Fera MT , La CameraE, De SarroA. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev. Anti Infect. Ther.7 (8), 981–998 (2009).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP , PattersonTF. Emergence of azole resistance in aspergillus. Semin. Respir. Crit. Care Med.36 (5), 673–680 (2015).
   PubMedGoogle Scholar
• Vazquez JA , ManavathuEK. Molecular characterization of a voriconazole-resistant, posaconazole-susceptible Aspergillus fumigatus isolate in a lung transplant recipient in the United States. Antimicrob. Agents Chemother.60 (2), 1129–1133 (2015).
   PubMed Web of Science ®Google Scholar
• Denning DW . Echinocandins: a new class of antifungal. J. Antimicrob. Chemother.49 (6), 889–891 (2002).
   PubMed Web of Science ®Google Scholar
• Denning DW . Echinocandin antifungal drugs. Lancet362 (9390), 1142–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Latge JP . The cell wall: a carbohydrate armour for the fungal cell. Mol. Microbiol.66 (2), 279–290 (2007).
   PubMed Web of Science ®Google Scholar
• Latge JP . Tasting the fungal cell wall. Cell. Microbiol.12 (7), 863–872 (2010).
   PubMed Web of Science ®Google Scholar
• Klis FM , De GrootP, HellingwerfK. Molecular organization of the cell wall of Candida albicans. Med. Mycol.39 (Suppl. 1), 1–8 (2001).
   PubMed Web of Science ®Google Scholar
• Chen SC , SlavinMA, SorrellTC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs71 (1), 11–41 (2011).
   PubMed Web of Science ®Google Scholar
• Franzot SP , CasadevallA. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformansin vitro. Antimicrob. Agents Chemother.41 (2), 331–336 (1997).
   PubMed Web of Science ®Google Scholar
• Abruzzo GK , FlatteryAM, GillCJet al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother.41 (11), 2333–2338 (1997).
   PubMed Web of Science ®Google Scholar
• Malhotra P , ShahSS, KaplanM, McgowanJP. Cryptococcal fungemia in a neutropenic patient with AIDS while receiving caspofungin. J. Infect.51 (3), e181–183 (2005).
   PubMedGoogle Scholar
• Arendrup MC , PerlinDS. Echinocandin resistance: an emerging clinical problem?Curr. Opin. Infect. Dis.27 (6), 484–492 (2014).
   PubMed Web of Science ®Google Scholar
• Shields RK , NguyenMH, PressEGet al. Rate of FKS mutations among consecutive Candida isolates causing bloodstream infection. Antimicrob. Agents Chemother.59 (12), 7465–7470 (2015).
   PubMedGoogle Scholar
• Luberto C , ToffalettiDL, WillsEAet al. Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev.15 (2), 201–212 (2001).
   PubMed Web of Science ®Google Scholar
• Aerts AM , FrancoisIE, BammensLet al. Level of M(IP)2C sphingolipid affects plant defensin sensitivity, oxidative stress resistance and chronological life-span in yeast. FEBS Lett.580 (7), 1903–1907 (2006).
   PubMedGoogle Scholar
• Leber A , FischerP, SchneiterR, KohlweinSD, DaumG. The yeast mic2 mutant is defective in the formation of mannosyl-diinositolphosphorylceramide. FEBS Lett.411 (2), 211–214 (1997).
   PubMedGoogle Scholar
• Saito K , TakakuwaN, OhnishiM, OdaY. Presence of glucosylceramide in yeast and its relation to alkali tolerance of yeast. Appl. Microbiol. Biotechnol.71 (4), 515–521 (2006).
   PubMedGoogle Scholar
• Rhome R , SinghA, KechichianTet al. Surface localization of glucosylceramide during Cryptococcus neoformans infection allows targeting as a potential antifungal. PLoS ONE6 (1), e15572 (2011).
   PubMed Web of Science ®Google Scholar
• Singh A , RellaA, SchwackeJ, Vacchi-SuzziC, LubertoC, Del PoetaM. Transmembrane transporter expression regulated by the glucosylceramide pathway in Cryptococcus neoformans. BMC Res. Notes8, 681 (2015).
   PubMedGoogle Scholar
• Del Poeta M , NimrichterL, RodriguesML, LubertoC. Synthesis and biological properties of fungal glucosylceramide. PLoS Pathog.10 (1), e1003832 (2014).
   PubMedGoogle Scholar
• Ramamoorthy V , CahoonEB, ThokalaM, KaurJ, LiJ, ShahDM. Sphingolipid C-9 methyltransferases are important for growth and virulence but not for sensitivity to antifungal plant defensins in Fusarium graminearum. Eukaryot. Cell8 (2), 217–229 (2009).
   PubMedGoogle Scholar
• Bertini S , ColomboAL, TakahashiHK, StrausAH. Expression of antibodies directed to Paracoccidioides brasiliensis glycosphingolipids during the course of paracoccidioidomycosis treatment. Clin. Vaccine Immunol.14 (2), 150–156 (2007).
   PubMedGoogle Scholar
• Toledo MS , LeverySB, StrausAH, TakahashiHK. Dimorphic expression of cerebrosides in the mycopathogen Sporothrix schenckii. J. Lipid Res.41 (5), 797–806 (2000).
   PubMedGoogle Scholar
• Zhu C , WangM, WangWet al. Glucosylceramides are required for mycelial growth and full virulence in Penicillium digitatum. Biochem. Biophys. Res. Commun.455 (3), 165–171 (2014).
   PubMedGoogle Scholar
• Oura T , KajiwaraS. Disruption of the sphingolipid Delta8-desaturase gene causes a delay in morphological changes in Candida albicans. Microbiology154 (Pt 12), 3795–3803 (2008).
   PubMedGoogle Scholar
• Oura T , KajiwaraS. Candida albicans sphingolipid C9-methyltransferase is involved in hyphal elongation. Microbiology156 (Pt 4), 1234–1243 (2010).
   PubMedGoogle Scholar
• Noble SM , FrenchS, KohnLA, ChenV, JohnsonAD. Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity. Nat. Genet.42 (7), 590–598 (2010).
   PubMed Web of Science ®Google Scholar
• Thevissen K , WarneckeDC, FrancoisIEet al. Defensins from insects and plants interact with fungal glucosylceramides. J. Biol. Chem.279 (6), 3900–3905 (2004).
   PubMed Web of Science ®Google Scholar
• Rodrigues ML , NimrichterL, OliveiraDLet al. Vesicular polysaccharide export in Cryptococcus neoformans is a eukaryotic solution to the problem of fungal trans-cell wall transport. Eukaryot. Cell6 (1), 48–59 (2007).
   PubMedGoogle Scholar
• Olsen I , JantzenE. Sphingolipids in bacteria and fungi. Anaerobe7 (2), 103–112 (2001).
   Google Scholar
• Barreto-Bergter E , PintoMR, RodriguesML. Structure and biological functions of fungal cerebrosides. An. Acad. Bras. Cienc.76 (1), 67–84 (2004).
   PubMed Web of Science ®Google Scholar
• Nimrichter L , RodriguesML. Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials. Front. Microbiol.2, 212 (2011).
   PubMedGoogle Scholar
• Li S , DuL, YuenG, HarrisSD. Distinct ceramide synthases regulate polarized growth in the filamentous fungus Aspergillus nidulans. Mol. Biol. Cell17 (3), 1218–1227 (2006).
   PubMed Web of Science ®Google Scholar
• Ternes P , WobbeT, SchwarzMet al. Two pathways of sphingolipid biosynthesis are separated in the yeast Pichia pastoris. J. Biol. Chem.286 (13), 11401–11414 (2011).
   PubMed Web of Science ®Google Scholar
• Takakuwa N , OhnishiM, OdaY. Significance of the KlLAC1 gene in glucosylceramide production by Kluyveromyces lactis. FEMS Yeast Res.8 (6), 839–845 (2008).
   PubMedGoogle Scholar
• Michaelson LV , ZaunerS, MarkhamJEet al. Functional characterization of a higher plant sphingolipid Delta4-desaturase: defining the role of sphingosine and sphingosine-1-phosphate in Arabidopsis. Plant Physiol.149 (1), 487–498 (2009).
   PubMed Web of Science ®Google Scholar
• Tani Y , AmaishiY, FunatsuTet al. Structural analysis of cerebrosides from Aspergillus fungi: the existence of galactosylceramide in A. oryzae. Biotechnol. Lett.36 (12), 2507–2513 (2014).
   PubMedGoogle Scholar
• Dickson RC . Thematic review series: sphingolipids. New insights into sphingolipid metabolism and function in budding yeast. J. Lipid Res.49 (5), 909–921 (2008).
   PubMed Web of Science ®Google Scholar
• Bertello LE , AlvesMJ, ColliW, De LederkremerRM. Inositolphosphoceramide is not a substrate for the first steps in the biosynthesis of glycoinositolphospholipids in Trypanosoma cruzi. Mol. Biochem. Parasitol.133 (1), 71–80 (2004).
   PubMedGoogle Scholar
• Whiteway M , BachewichC. Morphogenesis in Candida albicans. Annu. Rev. Microbiol.61, 529–553 (2007).
   PubMed Web of Science ®Google Scholar
• Rittenour WR , ChenM, CahoonEB, HarrisSD. Control of glucosylceramide production and morphogenesis by the Bar1 ceramide synthase in Fusarium graminearum. PLoS ONE6 (4), e19385 (2011).
   PubMedGoogle Scholar
• Insenser M , NombelaC, MoleroG, GilC. Proteomic analysis of detergent-resistant membranes from Candida albicans. Proteomics6 (Suppl. 1), S74–S81 (2006).
   PubMedGoogle Scholar
• Siafakas AR , WrightLC, SorrellTC, DjordjevicJT. Lipid rafts in Cryptococcus neoformans concentrate the virulence determinants phospholipase B1 and Cu/Zn superoxide dismutase. Eukaryot. Cell5 (3), 488–498 (2006).
   PubMedGoogle Scholar
• Nimrichter L , CerqueiraMD, LeitaoEAet al. Structure, cellular distribution, antigenicity, and biological functions of Fonsecaea pedrosoi ceramide monohexosides. Infect. Immun.73 (12), 7860–7868 (2005).
   PubMedGoogle Scholar
• Rodrigues ML , NosanchukJD, SchrankA, VainsteinMH, CasadevallA, NimrichterL. Vesicular transport systems in fungi. Future Microbiol.6 (11), 1371–1381 (2011).
   PubMed Web of Science ®Google Scholar
• Vargas G , RochaJD, OliveiraDLet al. Compositional and immunobiological analyses of extracellular vesicles released by Candida albicans. Cell. Microbiol.17 (3), 389–407 (2015).
   PubMed Web of Science ®Google Scholar
• Delgado A , CasasJ, LlebariaA, AbadJL, FabriasG. Inhibitors of sphingolipid metabolism enzymes. Biochim. Biophys. Acta1758 (12), 1957–1977 (2006).
   PubMed Web of Science ®Google Scholar
• Borghi E , MoraceG, BorgoFet al. New strategic insights into managing fungal biofilms. Front. Microbiol.6, 1077 (2015).
   PubMed Web of Science ®Google Scholar
• Lattif AA , MukherjeePK, ChandraJet al. Lipidomics of Candida albicans biofilms reveals phase-dependent production of phospholipid molecular classes and role for lipid rafts in biofilm formation. Microbiology157 (Pt 11), 3232–3242 (2011).
   PubMedGoogle Scholar
• Perdoni F , SignorelliP, CirasolaDet al. Antifungal activity of Myriocin on clinically relevant Aspergillus fumigatus strains producing biofilm. BMC Microbiol.15, 248 (2015).
   PubMed Web of Science ®Google Scholar
• De Melo NR , AbdrahmanA, GreigCet al. Myriocin significantly increases the mortality of a non-mammalian model host during Candida pathogenesis. PLoS ONE8 (11), e78905 (2013).
   PubMedGoogle Scholar
• Streit E , NaehrerK, RodriguesI, SchatzmayrG. Mycotoxin occurrence in feed and feed raw materials worldwide: long-term analysis with special focus on Europe and Asia. J. Sci. Food Agric.93 (12), 2892–2899 (2013).
   PubMedGoogle Scholar
• Mandala SM , ThorntonRA, FrommerBRet al. The discovery of australifungin, a novel inhibitor of sphinganine N-acyltransferase from Sporormiella australis. Producing organism, fermentation, isolation, and biological activity. J. Antibiot. (Tokyo)48 (5), 349–356 (1995).
   PubMed Web of Science ®Google Scholar
• Tidhar R , SimsK, Rosenfeld-GurE, ShawW, FutermanAH. A rapid ceramide synthase activity using NBD-sphinganine and solid phase extraction. J. Lipid Res.56 (1), 193–199 (2015).
   PubMed Web of Science ®Google Scholar
• Candido K , SioufiH, BandyopadhyayM, DasguptaS. Therapeutic impact of sphingosine 1-phosphatereceptor signaling in multiple sclerosis. Mini Rev. Med. Chem.16 (7), 547–554 (2015).
   Web of Science ®Google Scholar
• Proia RL , HlaT. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J. Clin. Invest.125 (4), 1379–1387 (2015).
   PubMed Web of Science ®Google Scholar
• Farnoud AM , BryanAM, KechichianT, LubertoC, Del PoetaM. The granuloma response controlling cryptococcosis in mice depends on the sphingosine kinase 1-sphingosine 1-phosphate Pathway. Infect. Immun.83 (7), 2705–2713 (2015).
   PubMed Web of Science ®Google Scholar
• Mcquiston T , LubertoC, Del PoetaM. Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophages. Microbiology157 (Pt 5), 1416–1427 (2011).
   PubMedGoogle Scholar
• Mcquiston T , LubertoC, Del PoetaM. Role of host sphingosine kinase 1 in the lung response against cryptococcosis. Infect. Immun.78 (5), 2342–2352 (2010).
   PubMed Web of Science ®Google Scholar
• Weiler S , BraendlinN, BeerliCet al. Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J. Med. Chem.57 (12), 5074–5084 (2014).
   PubMed Web of Science ®Google Scholar
• Bigaud M , GueriniD, BillichA, BassilanaF, BrinkmannV. Second generation S1P pathway modulators: research strategies and clinical developments. Biochim. Biophys. Acta1841 (5), 745–758 (2014).
   PubMed Web of Science ®Google Scholar
• Billich A , BeerliC, BergmannR, BrunsC, LoetscherE. Cellular assay for the characterization of sphingosine-1-phosphate lyase inhibitors. Anal. Biochem.434 (2), 247–253 (2013).
   PubMed Web of Science ®Google Scholar
• Mandala SM , HarrisGH. Isolation and characterization of novel inhibitors of sphingolipid synthesis: australifungin, viridiofungins, rustmicin, and khafrefungin. Methods Enzymol.311, 335–348 (2000).
   PubMed Web of Science ®Google Scholar
• Harris GH , ShafieeA, CabelloMAet al. Inhibition of fungal sphingolipid biosynthesis by rustmicin, galbonolide B and their new 21-hydroxy analogs. J. Antibiot. (Tokyo)51 (9), 837–844 (1998).
   PubMed Web of Science ®Google Scholar
• Mandala SM , ThorntonRA, MilliganJet al. Rustmicin, a potent antifungal agent, inhibits sphingolipid synthesis at inositol phosphoceramide synthase. J. Biol. Chem.273 (24), 14942–14949 (1998).
   PubMed Web of Science ®Google Scholar
• Heidler SA , RaddingJA. The AUR1 gene in Saccharomyces cerevisiae encodes dominant resistance to the antifungal agent aureobasidin A (LY295337). Antimicrob. Agents Chemother.39 (12), 2765–2769 (1995).
   PubMed Web of Science ®Google Scholar
• Aeed PA , YoungCL, NagiecMM, ElhammerAP. Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A. Antimicrob. Agents Chemother.53 (2), 496–504 (2009).
   PubMed Web of Science ®Google Scholar
• Wuts PG , SimonsLJ, MetzgerBP, SterlingRC, SlightomJL, ElhammerAP. Generation of broad-spectrum antifungal drug candidates from the natural product compound aureobasidin A. ACS Med. Chem. Lett.6 (6), 645–649 (2015).
   PubMed Web of Science ®Google Scholar
• Cerantola V , GuillasI, RoubatyCet al. Aureobasidin A arrests growth of yeast cells through both ceramide intoxication and deprivation of essential inositolphosphorylceramides. Mol. Microbiol.71 (6), 1523–1537 (2009).
   PubMed Web of Science ®Google Scholar
• Tan HW , TayST. The inhibitory effects of aureobasidin A on Candida planktonic and biofilm cells. Mycoses56 (2), 150–156 (2013).
   PubMed Web of Science ®Google Scholar
• Wang XH , GuoXJ, LiHY, GouP. Characteristics of inositol phosphorylceramide synthase and effects of aureobasidin A on growth and pathogenicity of Botrytis cinerea. J. Gen. Appl. Microbiol.61 (4), 108–116 (2015).
   PubMed Web of Science ®Google Scholar
• Sugimoto Y , SakohH, YamadaK. IPC synthase as a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord.4 (4), 311–322 (2004).
   PubMedGoogle Scholar